Polyomavirus-specific T cells - ViraCyte

Drug Profile

Polyomavirus-specific T cells - ViraCyte

Alternative Names: BKV-specific T cell therapy - ViraCyte; BKV-specific T cells - ViraCyte; HLA-matched BKV-specific T cells - ViraCyte; HLA-matched Viralym-B cells; Human leukocyte antigen (HLA)-matched BK virus-specific T lymphocytes - ViraCyte; Polyomavirus-specific T cell therapy - ViraCyte; Viralym-B

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViraCyte
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Human polyomavirus infections

Most Recent Events

  • 09 Apr 2018 Discontinued - Preclinical for Human polyomavirus infections in USA (IV) (NCT02313844)
  • 05 Jul 2017 ViraCyte receives SBIR grant from National Heart, Lung and Blood Institute for T cell immunotherapy development in Polyomavirus infections
  • 08 Dec 2014 Preclinical trials in Human polyomavirus infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top